Erlotinib Recruiting Phase 2 / 3 Trials for Metastatic Brain Tumors / EGFR Gene Mutations / Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

RecruitingTreatment2 / 3 IdentifierTitleDrugs
NCT02006043Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)
NCT02037997Safety and Effectiveness Study of Chemotherapy in Combination With Erlotinib,or Sequential Erlotinib for Treatment in Patients With NSCLC